Minerva Neurosciences Inc.

NERV

While we are advancing plans for an additional confirmatory Phase 3 clinical trial for roluperidone for the treatment of negative symptoms in schizophrenia, which we refer to as the C19 trial, in consultation with the FDA and expect to fund such trial and our resubmission of the NDA in part with net proceeds from our October 2025 private placement, there can be no assurances that we will succes…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$123M

EPS-$36.74

P/E-0.07

P/FCF-4.69

EV/EBITDA-1.35

FCF Yield–

Div. Yield–

Net Debt/FCF2.9x

Minerva Neurosciences Inc. intrinsic value

52-Week Range

$2.20$7.69

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$394M

▼ -20492.7% YoY

Op. Margin

–

ROIC

–

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$26M

▲ +30.9% YoY

Op. Cash Flow (TTM)

-$26M

▲ +30.9% YoY

Net Debt

-$75M

Net Cash Position

Cash & Equiv.

$75M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with NERV

CompareIntrinsic value

CELUCelularity Inc.

$0.81-1.00%0

CRNXCrinetics Pharmaceuticals Inc.

No recent price40

WVEWave Life Sciences Ltd.

$3.62+1.12%40

BFRIBiofrontera Inc.

$0.90+1.55%30

CUECue Biopharma, Inc.

$19.84-4.89%40

VTVTvTv Therapeutics Inc.

$24.03+2.04%40

NRIXNurix Therapeutics Inc.

$15.95-38.23%84

FHTXFoghorn Therapeutics Inc.

$2.10-1.41%40

Held by ETFs

NERV is in 3 US ETFs. The largest of them, with NERV's weight in each:

Minerva Neurosciences (NERV) in three numbers

Quality score: 10/100; Best check: net debt, -$75M. Weakest: share count change, 1381.3%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -0.07; Negative: a loss over the last twelve months. Price to free cash flow -4.69.; Financials

Questions about Minerva Neurosciences

Is Minerva Neurosciences a high-quality business?

Minerva Neurosciences scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is net debt at -$75M, and its weakest is share count change at 1381.3%. The Quality tab shows every check against its target.

Does Minerva Neurosciences (NERV) pay a dividend?

No. Minerva Neurosciences (NERV) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 4 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in NERV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NERV

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.